Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Buy" by Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are currently covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have covered the stock in the last year is $6.63.

A number of research analysts have recently issued reports on TSHA shares. Canaccord Genuity Group lifted their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a report on Friday, November 15th. Chardan Capital restated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Finally, Needham & Company LLC restated a "buy" rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, February 27th.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ:TSHA remained flat at $1.72 on Tuesday. The stock had a trading volume of 3,274,544 shares, compared to its average volume of 2,673,386. Taysha Gene Therapies has a twelve month low of $1.19 and a twelve month high of $4.32. The business has a 50-day moving average of $1.66 and a 200 day moving average of $1.94. The firm has a market capitalization of $352.60 million, a price-to-earnings ratio of 2.73 and a beta of 0.91. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Remove Ads

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. As a group, equities research analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently modified their holdings of TSHA. Octagon Capital Advisors LP raised its holdings in Taysha Gene Therapies by 128.6% in the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock worth $18,078,000 after purchasing an additional 5,877,778 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in Taysha Gene Therapies in the 4th quarter worth about $8,650,000. Bank of America Corp DE raised its holdings in Taysha Gene Therapies by 1,178.9% in the 4th quarter. Bank of America Corp DE now owns 1,710,303 shares of the company's stock worth $2,959,000 after purchasing an additional 1,576,568 shares during the period. Norges Bank acquired a new position in Taysha Gene Therapies in the 4th quarter worth about $2,528,000. Finally, Avoro Capital Advisors LLC raised its holdings in Taysha Gene Therapies by 7.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock worth $34,600,000 after purchasing an additional 1,349,999 shares during the period. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.